Leprosy initially misdiagnosed as sarcoidosis, adult-onset still disease, or autoinflammatory disease. by Simeoni S et al.
Copyright @ 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
ARTICLE COVERSHEET
LWW_CONDENSED-FLA(7.75X10.75)
SERVER-BASED
Template version : 5.6
Revised: 09/26/2011
Article : RHU20857
Creator : gi68
Date : Thursday October 20th 2011
Time : 06:46:25
Number of Pages (including this page) : 6
Copyright @ 2011 Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited.
Leprosy Initially Misdiagnosed as Sarcoidosis, Adult-Onset
Still Disease, or Autoinflammatory Disease
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Abstract: Leprosy is a chronic granulomatous disease caused by My-
cobacterium leprae. We describe the case of a 20-year-old man from
India living in Italy since 2003, who presented with erythematous pap-
ules and nodules distributed on his arms, legs, and face in 2006. He also
had episodes of high fever, polyarthritis, and episcleritis. Sarcoidosis was
suspected on the basis of elevated angiotensin-converting enzyme and
bronchoalveolar lavage fluid, and the patient was treated with corticos-
teroids for about a year. A flare of the disease occurred each time corti-
costeroid was tapered or suspended. An autoinflammatory disease was
then suspected and treated with immunosuppressant. Only the third deep
skin biopsy revealed the presence of M. leprae. The lack of clinical sus-
picion and the unfamiliarity with the histology of leprosy delayed diag-
nosis and treatment. Leprosy should be considered in the differential
diagnoses of patients presenting with rheumatic and cutaneous manifes-
tations especially when they come from countries where the disease is
endemic.
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H ansen disease (HD), known as leprosy, is a chronic granu-lomatous disease affecting the skin and nerves caused
by Mycobacterium leprae, an obligate intracellular infectious
agent.1,2 Leprosy continues to be a challenge to health world-
wide, with about 250,000 new cases being detected every
year, and it is the leading infectious cause of disability.3 Myco-
bacterium leprae is spread principally by aerosolized droplets
from nasal secretions and may rarely enter through broken
skin. Human beings are the principal reservoir of infection,
except in the Americas, where armadillos also provide a reser-
voir.3 Most people are not susceptible to leprosy and after ex-
posure to the bacterium do not develop the disease. Those who
do, after an incubation period of several years (2Y12 years),
may have only a single lesion that spontaneously heals in 75%
of cases.1,3
Polymorphisms of the tumor necrosis factor >, interleu-
kin 10, or interferon F promoter region have been shown to be
associated with increased susceptibility or with resistance to
leprosy.2,4 A genome-wide association study of leprosy patients
and healthy controls identified new associations between var-
iants of the NOD2-mediated signaling pathway, which regu-
lates the innate immune response and the risk and form of the
disease.3 Moreover, innate immune response, in particular the
role of pattern recognition receptors in recognizing pathogen-
associated molecular patterns of M. leprae, has been recently
studied and has provided insight into immunoregulation in
human infectious disease.5,6 The type of immune response to
the infection, that is, a prevalent cell-mediated or humoral re-
sponse, determines the type of the disease: tuberculoid HD is
the result of a cell-mediated response, whereas lepromatous
HD is of a humoral response.7 Between these 2 types of dis-
ease, there are the borderline leprosy types, in which patients
have some cell-mediated immune response, multiple lesions, and
unstable immunity.3
Although HD may have classic features such as erythem-
atous or hypopigmented plaques and alopecia, HD is like a
chameleon. Clinically, it can resemble many entities, such as sys-
temic lupus erythematosus,8 sarcoidosis, cutaneous leishmaniasis,
tertiary syphilis, lymphomas, systemic mycosis, traumatic le-
sions and malignant neoplasms, tinea, contact dermatitis, vitili-
go, pityriasis alba, or myxedema.2,7 Histologically, HD ranges
from paucibacillary forms, in which there are essentially no
bacilli, to multibacillary forms with countless bacilli.7 Tests for
HD include serologic assays, slit-skin smears, biopsies, probes,
polymerase chain reaction, and the lepromin test.1,7 Conclu-
sive diagnosis can be made on finding Kinyoun-negative acid-
fast bacilli in an appropriate histologic background such as in
nerves or in foamy histiocytes (lepra cells). The diagnosis is
less clear in paucibacillary lesions and/or treated cases. Treat-
ment is difficult, and it must be continued for long periods
and may be complicated by severe adverse reactions. The most
commonly used drugs are dapsone, rifampicin, and clofazmine.1,2
Quinolones, such as ofloxacin and pefloxacin, as well as some
macrolides, such as clarithromycin and minocycline, are also
effective.9
CASE REPORT
We present a 20-year-old man who moved to Italy from
India in 2003; in September 2006, he was admitted to a hos-
pital in northern Italy for the presence of high continuous fe-
ver; erythematous papules, macules, and nodules on his arms,
legs, and face, with no hypopigmentation or anesthesia; arthri-
tis of the wrists and ankles; and episcleritis in both eyes
( F1Figs. 1AYC). His family history was noncontributory (at first
he denied any familiar disease), and his medical history was
otherwise unremarkable.
Laboratory investigations showed neutrophilic leukocyto-
sis (white blood cells, 21,400/KL; neutrophils, 87%), very high
erythrocyte sedimentation rate (65 mm in the first hour; normal
value, G22 mm/hr) and C-reactive protein (300 mg/L; normal
value, G5 mg/L), and increased serum angiotensin-converting
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enzyme (ACE) (101.0 IU/L; normal value, 8Y54 IU/L). Liver
and kidney function tests, thyroid hormones, protein electro-
phoresis, and serum levels of IgM, IgG, and IgA were normal.
Serum antinuclear antibodies, rheumatoid factor, anticitrulline
antibodies, anticardiolipin antibodies, and antineutrophil cyto-
plasmic antibodies were negative. Complement fractions 3 and
4 were normal. Lactate dehydrogenase, creatine phosphokinase,
and aldolase were normal. Blood cultures and antibodies against
bacteria and viruses were negative.
Chest x-ray, abdomen ultrasonography, transthoracic echo-
cardiogram, and x-ray of the hands, wrists, and ankles did not
show abnormalities. Chest computed tomography showed a non-
specific, diffuse interstitial lung disease. Analysis of bronchoal-
veolar lavage fluid showed an increase in lymphocytes (30%)
and macrophages (70%) and an increased ratio of CD4 to CD8
T lymphocytes (5.1; normal value, G3).
Although no skin or transbronchial biopsy was performed
on that occasion, ‘‘possible sarcoidosis with prevalent extra-
pulmonary involvement’’ was diagnosed, and the patient was
administered high-dose corticosteroid therapy (1 mg/kg per day)
with sudden clinical improvement. After 6 months when the
tapering of prednisolone reached 12.5 mg/d, a severe flare of
the disease occurred with the same symptoms present at the
beginning of the disease. On that occasion, a gallium (Ga) 67
scintigraphy revealed accumulation of Ga at the orbits, wrists,
and skin lesions. No evidence of pulmonary accumulation of
FIGURE 1. PomphoidAQ1 erythematous lesions on the leg (A), face (B), and arm (C). Color online figure is available at
http://www.jclinrheum.com.
FIGURE 2. Features of leprosy in the skin biopsy. A, Collection of macrophages with bubbly and grayish cytoplasm in the dermis.
The leprosy bacilli may be arranged in large groups or globi in histiocytes (arrow) or vascular endothelium (head arrow)
(hematoxylin-eosin stain, magnification:  40). B, Small nerve infiltrated by lepra cells into the subcutaneous fat (hematoxylin-eosin,
magnification:  20). C, Erythema nodosum leprosum features: numerous neutrophils are intermingling with the lepra cells
(hematoxylin-eosin, magnification:  26). D, Ziehl-Neelsen stain reveals acid-fast bacilli (magnification:  40).
E, Numerous acid-fast bacilli (oil immersion). Color online figure is available at http://www.jclinrheum.com.
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Ga was present. On the basis of the clinical history, the diag-
nosis of sarcoidosis was considered unlikely, and a possible
adult-onset Still disease was taken into account, although the
ferritin level was not very high: 817 Kg/L (normal value,
30Y250 Kg/L). The dosage of prednisolone was increased to
50 mg/d with immediate beneficial effects, and methotrexate
10 mg/wk plus hydroxychloroquine 200 mg/d were added as
corticosteroid-sparing agents. In November 2007, the patient
was admitted to the casualty area because of an acute perfo-
rated appendicitis treated with open appendicectomy. Cortico-
steroid and immunosuppressive therapy was stopped for a week,
but in a few days, there was a severe relapse of dermal lesions
with high temperature and all the clinical symptoms previ-
ously described. The patient was readmitted to the same hospi-
tal in December 2007, and a biopsy of a dermal lesion of the
arm was performed: no evidence of epithelioid granuloma was
found, and a severe dermal reaction to hydroxychloroquine was
suggested because of the presence of superficial and deep peri-
vascular dermatitis characterized by a mixed infiltration of lym-
phocytes, histiocytes, and neutrophils and presence of dermal
edema and subepidermal vesicles with necrosis of the epidermis.
The patient restarted prednisolone therapy at 50 mg/d and
methotrexate 10 mg/wk. In February 2008, a second skin bi-
opsy was performed, and the features were again nonspecific,
suggesting either a possible poststeroid panniculitis or a Sweet
syndrome with hypodermal involvement or an erythema nodo-
sum with dermal involvement.
In June 2008, when prednisolone was tapered to 20 mg/d,
the patient had another flare of the disease and was admitted
to our Unit of Autoimmune Diseases. We decided to stop cor-
ticosteroids and to start treatment with ibuprofen, suspecting
an autoinflammatory disease such as periodic fever or Schnitzler
syndrome. In that occasion, laboratory tests confirmed high
levels of erythrocyte sedimentation rate (97 mm in the first
hour; normal value, G14 mm/hr), C-reactive protein (173 mg/L;
normal value, G5 mg/L), and fibrinogen: 787 mg/dL (normal
value, 150Y400 mg/dL). Full blood count showed the presence
of leukocytosis (16,120/KL with 87% of neutrophils), mild
hypochromic-microcytic anemia (hemoglobin, 11 g/dL; normal
value, 13Y17 g/dL), and thrombocytosis (441,000/KL; normal
value, 150Y400/KL), interpreted as related to chronic inflam-
mation. Autoantibodies were again negative, and serum ferritin
was 417 Kg/L (normal value, 30Y250 Kg/L). Because the di-
agnosis was still undefined, and a good response was present
only to high dose of corticosteroids and because the blood tests
were suggestive of an important inflammatory state, we de-
cided to perform a third deep (dermal-hypodermal) skin biopsy.
Leprosy was diagnosed by finding acid-fast bacilli, indic-
ative of M. leprae, within macrophages (F2 Figs. 2AYE). A his-
tory of exposure (as a child when in India, he had been living
for a long time with an uncle affected by leprosy) was at that
moment reported by the patient and his parents. The patient
was then referred to the Italian National Centre for Leprosy at
San Martino Hospital in Genova and started multidrug therapy/
World Health organization. He was therefore administered ri-
fampicin, clofazimine, and dapsone plus prednisolone 25 mg/d
with a good response to the treatment. He is still followed up at
the National Centre for Leprosy in Genova, and at the moment,
he is taking rifampicin, minocycline, and prednisolone.
DISCUSSION
We describe here the case of a patient with lepromatous lep-
rosy, acquired within a contagious family setting during child-
hood and adolescence, diagnosed as a possible sarcoidosis first
and then as an autoimmune/autoinflammatory disorder. The re-
sults of bronchoalveolar lavage and the high levels of serum ACE
probably induced the physicians to consider an acute-onset sar-
coidosis as the first possible diagnosis, although no biopsy was
performed at that time. As already reported, sarcoidosis can mimic
lepromatous leprosy.10 Indeed, high levels of ACE are present
also in leprosy,8,11 in particular in patients with Lucio phe-
nomenon,12Y14 a leprosy reaction characterized by skin ulcer-
ations and by systemic manifestations that occurs after 1 to
3 years from the first manifestations of the disease. It seems to
be due to a severe immune response deficiency with free repli-
cation of M. leprae in endothelial cells followed by vasculitis,
thrombosis, and necrosis.13 Lucio phenomenon typically affects
patients from Central and South America.
Leprosy reactions are characterized by the appearance of
symptoms and signs of acute inflammation in the lesions and are
due to acute hypersensitivity to antigens of M. leprae.13 Type I
reactions, associated with cell-mediated hypersensitivity, are
also called reversal reaction, occur primarily in borderline lep-
rosy, and are characterized by skin changes and neuritis. Type II
reactions are associated with immune complex deposition, oc-
cur in patients with multibacillary disease, and cause acute in-
flammation in any organ or tissue where the mycobacterium is
found. It is clinically expressed as erythema nodosum, neuri-
tis, bone pain and arthralgias, fever, malaise, iritis, orchitis, and
so on.13 Three different clinical variants of type II leprosy re-
actions are described: (1) erythema nodosum leprosum (ENL),
(2) erythema polymorphous-like reaction, and (3) Lucio phe-
nomenon. However Lucio phenomenon is sometimes desig-
nated as type III reaction.15
Erythema nodosum leprosum is the most common form
of type II leprosy reaction and affects patients with the lepro-
matous spectrum of the disease like the patient we have de-
scribed here. Indeed, ENL is characterized by erythematous or
deep purple nodules, variably distributed on the body, mostly
occurring on the legs, arms, and face. On the contrary, idio-
pathic erythema nodosum is confined to the anterior portion
of the lower legs. It is therefore possible that our patient showed
an ENL, although this is usually a complication of the treat-
ment. Prednisolone and methotrexate have been proposed as a
possible therapy in resistant ENL.16 In the patient we describe
here, corticosteroid and immunosuppressive therapy obtained
an apparent response for their effect on the immune response
that is responsible for the majorities of the leprosy reactions.
Hansen disease is unfamiliar to European clinicians and
pathologists, and lack of clinical suspicion and unfamiliarity
with the histology of indeterminate leprosy delayed diagnosis
and treatment in the patient we describe here.
Typical cutaneous and neurologic manifestations of lep-
rosy are more easily diagnosed. Indeed, it is important to rec-
ognize the infection as early as possible so that early nerve
damage can be identified and treated rapidly.
However, leprosy can mimic several rheumatologic disor-
ders, and physicians sometimes ignore that leprosy may present
with rheumatic symptoms. A plethora of rheumatic manifesta-
tions is associated with leprosy, particularly with lepra reac-
tions.17 Paira and Roverano18 investigated the rheumatic and
laboratory features in 25 patients with HD and found that 16
(64%) developed a broad range of rheumatic manifestations,
the most common being a distinctive syndrome of swollen
hands observed in 10 patients (66.5%). These manifestations
were more frequent in patients with lepromatous leprosy.
In a similar work, Vengadakrishnan et al.19 studied 70 cases
of leprosy and found that arthritis may be the first symp-
tom of leprosy and that rheumatic manifestations are present in
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61.42% of cases. In particular, arthritis was seen in 54.28%
and presented as symmetric peripheral polyarthritis most com-
monly involving the knee, elbow, and the metacarpophalan-
geal and interphalangeal joints of the hands, clinically similar
to rheumatoid arthritis. Musculoskeletal manifestations can oc-
cur at any time during the infection. All patients with arthritis
were subjected to x-ray of the affected joints, and nonspecific
changes were commonly found. Also sacroiliitis (based on the
presence of sclerosis, erosions, and narrowing of the cartilage
space in the sacroiliac joints with or without low back pain) is
often present in patients with leprosy.20
Laboratory abnormalities in leprosy include an elevated sed-
imentation rate in 100% of the patients, the presence of auto-
antibodies such as rheumatoid factor in 18.7%, and presence
of antinuclear antibodies in 3.1%.21 In a more recent study,
however, both rheumatoid factor and antiYcyclic citrullinated
peptide antibodies were present in a similar percentage in le-
promatous patients and in normal subjects.22
Interestingly, 42% of multibacillary and 17% of pauciba-
cillary leprosy patients have been found positive for antiYA2
glycoprotein I IgM,23 suggesting the presence of an autoim-
mune response induced by M. leprae chronic infection.
Bacterial infections such as tuberculosis and leprosy; viral
arthropathies such as O’nyong-nyong, chikungunya, and den-
gue; and parasitic infections such as filariasis, schistosomia-
sis, and amebiasis may present with rheumatic manifestations.24
With the increasing world traveling and migration, internal med-
icine, rheumatology, and clinical immunology specialists must
be aware of these aspects in clinical practice.
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